Physician profile

Ramon Flores

Hackensack, NJ

NPI 1043279227

$452.89

in general payments reported to CMS, 2019-2025

6 companies · $144 in 2025

The $144 reported for 2025 was more than what a typical provider received nationally.

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$242.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $197.60 2019-2025 Bexsero, Pediarix, Rotarix
Merck Sharp & Dohme LLC $108.80 2022-2025 Gardasil 9, Vaxneuvance, M-M-R II
Kowa Pharmaceuticals America, INC. $90.26 2024-2025 Zoryve
Genentech USA, INC. $26.43 2019-2022
Organon LLC $15.85 2025
Cranial Technologies, INC $13.95 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ramon Flores

$452.89

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $144 reported for 2025 was more than what a typical provider received nationally.

https://glasscript.com/doctor/1383516/ramon-flores

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.